Cargando…
The 1‑year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study
BACKGROUND: Diabetes mellitus (DM) patients show higher rates of repeat revascularisation even in the era of modern drug-eluting stents (DES). The concept of bioresorbable scaffolds is becoming captivating, as it might allow for repeat interventions, prolonging the time span during which patients ca...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bohn Stafleu van Loghum
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823340/ https://www.ncbi.nlm.nih.gov/pubmed/31197750 http://dx.doi.org/10.1007/s12471-019-1293-7 |
_version_ | 1783464507460288512 |
---|---|
author | Hommels, T. M. Hermanides, R. S. Rasoul, S. Berta, B. IJsselmuiden, A. J. J. Jessurun, G. A. J. Benit, E. Pereira, B. De Luca, G. Kedhi, E. |
author_facet | Hommels, T. M. Hermanides, R. S. Rasoul, S. Berta, B. IJsselmuiden, A. J. J. Jessurun, G. A. J. Benit, E. Pereira, B. De Luca, G. Kedhi, E. |
author_sort | Hommels, T. M. |
collection | PubMed |
description | BACKGROUND: Diabetes mellitus (DM) patients show higher rates of repeat revascularisation even in the era of modern drug-eluting stents (DES). The concept of bioresorbable scaffolds is becoming captivating, as it might allow for repeat interventions, prolonging the time span during which patients can be treated by percutaneous coronary intervention (PCI). AIMS: We intend to evaluate the short- and long-term safety and efficacy of Absorb bioresorbable vascular scaffolds (Absorb BVS) in the treatment of coronary artery disease (CAD) in DM patients for any indication. METHODS: The ABSORB DM Benelux is an international prospective study in DM patients who have undergone PCI with ≥1 Absorb BVS. Major adverse cardiac events (MACE) at 1 year was the primary endpoint, defined as a composite of all-cause death, any myocardial infarction (MI) and ischaemia-driven target vessel revascularisation (TVR). Secondary endpoints were target lesion failure (TLF) and definite or probable scaffold thrombosis (ScT). RESULTS: Between April 2015 and March 2017, 150 DM patients and 188 non-complex lesions were treated. Device implantation was successful in 100%. MACE occurred in 14 (9.5%) patients, with all-cause death occurring in 4 (2.7%), any MI in 6 (4.1%) and ischaemia-driven TVR in 7 (4.8%) respectively. TLF was reported in 11 (7.5%). Definite and probable ScT was observed in 2 (1.4%). CONCLUSION: Absorb BVS for treatment of anatomically low-risk patients with DM show acceptable safety and efficacy outcomes at 1 year. If these promising results are confirmed after a longer follow-up period, new-generation bioresorbable scaffolds combined with refinement of implantation techniques might open new horizons for CAD treatment in DM patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12471-019-1293-7) contains supplementary material, which is available to authorised users. |
format | Online Article Text |
id | pubmed-6823340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Bohn Stafleu van Loghum |
record_format | MEDLINE/PubMed |
spelling | pubmed-68233402019-11-14 The 1‑year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study Hommels, T. M. Hermanides, R. S. Rasoul, S. Berta, B. IJsselmuiden, A. J. J. Jessurun, G. A. J. Benit, E. Pereira, B. De Luca, G. Kedhi, E. Neth Heart J Original Article BACKGROUND: Diabetes mellitus (DM) patients show higher rates of repeat revascularisation even in the era of modern drug-eluting stents (DES). The concept of bioresorbable scaffolds is becoming captivating, as it might allow for repeat interventions, prolonging the time span during which patients can be treated by percutaneous coronary intervention (PCI). AIMS: We intend to evaluate the short- and long-term safety and efficacy of Absorb bioresorbable vascular scaffolds (Absorb BVS) in the treatment of coronary artery disease (CAD) in DM patients for any indication. METHODS: The ABSORB DM Benelux is an international prospective study in DM patients who have undergone PCI with ≥1 Absorb BVS. Major adverse cardiac events (MACE) at 1 year was the primary endpoint, defined as a composite of all-cause death, any myocardial infarction (MI) and ischaemia-driven target vessel revascularisation (TVR). Secondary endpoints were target lesion failure (TLF) and definite or probable scaffold thrombosis (ScT). RESULTS: Between April 2015 and March 2017, 150 DM patients and 188 non-complex lesions were treated. Device implantation was successful in 100%. MACE occurred in 14 (9.5%) patients, with all-cause death occurring in 4 (2.7%), any MI in 6 (4.1%) and ischaemia-driven TVR in 7 (4.8%) respectively. TLF was reported in 11 (7.5%). Definite and probable ScT was observed in 2 (1.4%). CONCLUSION: Absorb BVS for treatment of anatomically low-risk patients with DM show acceptable safety and efficacy outcomes at 1 year. If these promising results are confirmed after a longer follow-up period, new-generation bioresorbable scaffolds combined with refinement of implantation techniques might open new horizons for CAD treatment in DM patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12471-019-1293-7) contains supplementary material, which is available to authorised users. Bohn Stafleu van Loghum 2019-06-13 2019-11 /pmc/articles/PMC6823340/ /pubmed/31197750 http://dx.doi.org/10.1007/s12471-019-1293-7 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Hommels, T. M. Hermanides, R. S. Rasoul, S. Berta, B. IJsselmuiden, A. J. J. Jessurun, G. A. J. Benit, E. Pereira, B. De Luca, G. Kedhi, E. The 1‑year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study |
title | The 1‑year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study |
title_full | The 1‑year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study |
title_fullStr | The 1‑year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study |
title_full_unstemmed | The 1‑year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study |
title_short | The 1‑year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study |
title_sort | 1‑year safety and efficacy outcomes of absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the absorb dm benelux study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823340/ https://www.ncbi.nlm.nih.gov/pubmed/31197750 http://dx.doi.org/10.1007/s12471-019-1293-7 |
work_keys_str_mv | AT hommelstm the1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT hermanidesrs the1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT rasouls the1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT bertab the1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT ijsselmuidenajj the1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT jessurungaj the1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT benite the1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT pereirab the1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT delucag the1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT kedhie the1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT hommelstm 1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT hermanidesrs 1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT rasouls 1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT bertab 1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT ijsselmuidenajj 1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT jessurungaj 1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT benite 1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT pereirab 1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT delucag 1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy AT kedhie 1yearsafetyandefficacyoutcomesofabsorbbioresorbablevascularscaffoldsforcoronaryarterydiseasetreatmentindiabetesmellituspatientstheabsorbdmbeneluxstudy |